Bayer Oct. 27 announced Dr. Christian Rommel as the new Head of Research and Development at its Pharmaceuticals Division, effective February 1, 2021, the company informed in the press release.
He will report to Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of Pharmaceuticals. Rommel will serve on the Pharmaceuticals Executive Committee and be based in Berlin. Prior to joining Bayer, he held top manager positions at the Oncology Research and Early Development at Hoffmann-La Roche AG in Basel.
Christian Rommel will succeed Dr. Joerg Moeller who decided to leave Bayer, effective December 31, 2020, to pursue other career opportunities. His prior positions include executive-level R&D roles at Amgen, Intellikine as well as scientific leadership positions at Merck Serono and Regeneron.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth.
